Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Christian K. Kollmannsberger
University of British Columbia (UBC)
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
97
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer
Number of pages: 41
Posted: 12 Jun 2024
Abha A. Gupta
,
Anna V. Tinker
,
Derek Jonker
,
Rahima Jamal
,
Hal Hirte
,
Eric Winquist
,
Quincy Chu
, Christian K. Kollmannsberger,
Ralph Wong
,
Thierry Alcindor
,
Torsten O. Nielsen
,
Ming Tsao
,
Tricia R. Cottrell
,
Diane Provencher
,
John Hilton
,
Monika Krzyzanowska
,
Christine Elser
,
Sebastien Hotte
,
Joanna Sederias
,
Siwei Zhang
,
Wei Tu
and
Janet Dancey
The Hospital for Sick Children, BC Cancer, University of Ottawa - Ottawa Hospital Research Institute, University of Montreal - Notre-Dame Hospital, Juravinski Hospital - Cancer Centre, Western University, Canada, Cross Cancer Institute, University of British Columbia (UBC), CancerCare Manitoba, University of British Columbia (UBC), University of British Columbia (UBC), University of Toronto - University Health Network, University of Toronto - Princess Margaret Cancer Centre, University of Montreal - Notre-Dame Hospital, University of Ottawa - Ottawa Hospital Research Institute, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - University Health Network, Juravinski Hospital - Cancer Centre, Canadian Cancer Trials Group, Canadian Cancer Trials Group, Canadian Cancer Trials Group and Canadian Cancer Trials Group
Downloads
97
(704,534)
View PDF
Download
Abstract:
checkpoint inhibitors, rare cancers, ovarian carcinoma
Feedback